

Supplemental Table 1. Pharmacokinetic parameters of mirogabalin

	Diazepam study		Pregabalin study	
	15 mg N = 35	45 mg N = 37	15 mg N = 50	60 mg N = 52
C_{max} , ng/mL	198 (51.6)	561 (129)	202 (44)	756 (176)
Geometric mean (CV%)	192 (25.68)	547 (23.02)	197 (22.88)	736 (24.03)
T_{max} , h				
Median (min, max)	1.00 (1.00–2.00)	1.00 (1.00–2.00)	1.08 (1.08–2.08)	1.08 (1.08–3.08)
AUC_{last} , ng·h/mL	683 (130)	2047 (35)	751 (153)	3060 (576)
Geometric mean (CV%)	672 (18.57)	2017 (17.54)	736 (20.05)	3010 (18.55)
AUC_{inf} , ng·h/mL	700 (131)	2072 (357)	768 (153)*	3090 (579)
Geometric mean (CV%)	689 (18.17)	2041 (17.63)	754 (19.48)*	3040 (18.49)
$t_{1/2}$, h	3.3 (0.7)	3.8 (0.4)	3.2 (0.6)*	3.5 (0.4)

Shown as arithmetic mean (standard deviation), unless otherwise noted.

*N = 49.

AUC_{inf} , area under the plasma concentration vs time curve at infinity; AUC_{last} , area under the plasma concentration vs time curve from time 0 to the last quantifiable dose; C_{max} , maximum plasma concentration; CV%, coefficient of variation; $t_{1/2}$, terminal elimination half-life; T_{max} , time to reach maximum plasma concentration.

Supplemental Table 2. Summary of treatment emergent adverse events reported in $\geq 5\%$ of subjects in any one treatment group by primary system organ class and preferred term (assessment phase). A) Diazepam study. B) Pregabalin study.

A)

Diazepam study (Safety analysis set)				
Placebo N = 35	MGB 15 mg N = 35	MGB 45 mg N = 37	DZP 15 mg N = 36	DZP 30 mg N = 35

Any	10 (28.6)	3 (8.6)	10 (27.0)	25 (69.4)	28 (80.0)
Cardiac Disorders	2 (5.7)	2 (5.7)	2 (5.4)	3 (8.3)	2 (5.7)
Postural Orthostatic Tachycardia Syndrome	2 (5.7)	2 (5.7)	2 (5.4)	3 (8.3)	2 (5.7)
General disorders					
Feeling of relaxation	2 (5.7)	1 (2.9)	0	6 (16.7)	4 (14.3)
Nervous system disorders	3 (8.6)	1 (2.9)	6 (16.2)	15 (41.7)	20 (57.1)
Dizziness	0	0	0	2 (5.6)	2 (5.7)
Sedation	2 (5.7)	0	3 (8.1)	12 (33.3)	19 (54.3)
Somnolence	0	0	2 (5.4)	1 (2.8)	0
Balance disorder	0	0	0	0	2 (5.7)
Psychiatric disorders					
Elevated mood	0	0	0	0	6 (17.1)

B)

Pregabalin study (Safety analysis set)					
	Placebo N = 52	MGB 15 mg N = 50	MGB 60 mg N = 52	MGB 105 mg N = 50	PGB 200 mg N = 51
Any	19 (36.5)	18 (36.0)	35 (67.3)	45 (90.0)	24 (47.1)
Cardiac disorders	3 (5.8)	6 (12.0)	5 (9.6)	11 (22.0)	2 (3.9)
Postural orthostatic Tachycardia syndrome	3 (5.8)	5 (10.0)	5 (9.6)	11 (22.0)	2 (3.9)
Nervous system disorders	7 (13.5)	5 (10.0)	14 (26.9)	21 (42.0)	10 (19.6)
Dizziness	0	1 (2.0)	3 (5.8)	4 (8.0)	2 (3.9)
Headache	3 (5.8)	1 (2.0)	3 (5.8)	5 (10.0)	2 (3.9)
Somnolence	3 (5.8)	2 (4.0)	11 (21.2)	15 (30.0)	6 (11.8)
Psychiatric disorders					
Euphoric mood	5 (9.6)	5 (10.0)	28 (53.8)	34 (68.0)	12 (23.5)

Values shown as n (%).

DZP, diazepam; MGB, mirogabalin; PGB, pregabalin.